Technology area: Biotechnology & Pharmaceuticals
43 pending office actions • 27 art units • 41 examiners • 0 of 43 (0%) have an AI response strategy ready • 51 patents granted in the last 365 days
Memorial Sloan Kettering Cancer Center has 41 pending office actions in Biotechnology & Pharmaceuticals. The matters span 38 examiners and 27 art units, demonstrating wide distribution across examination personnel and technical groupings. Because the action volume exceeds both other measures, some examiners and art units handle multiple matters.
TICHY, JENNIFER M.H. is the busiest examiner, with 2 pending matters. That is the largest examiner-specific assignment shown, but it represents only a small part of the overall docket. Counsel should therefore use portfolio systems that distinguish recurring art-unit issues from examiner-specific treatment.
The 27 art-unit settings support technical clustering for prior-art review, claim language, and disclosure consistency. At the same time, the 38 examiner relationships require individualized prosecution histories and careful deadline control. Central coordination is useful, but response strategy must remain tailored to each examination record.
Based on the USPTO statutory response window for each pending office action. 16 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 16 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 5 (12%) |
| §103 only | 9 (21%) |
| §102 only | 1 (2%) |
| §112 only | 6 (14%) |
| Double-patenting only | 1 (2%) |
| Double-patenting + other | 5 (12%) |
| Multi-statute (no §101) | 15 (35%) |
| No statute on record | 1 (2%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TICHY, JENNIFER M.H. | 2 | 64.6% | +34.4% |
| TRAN, KHOA NHAT | 2 | 41.9% | +50.5% |
| NEAGU, IRINA | 1 | 46.7% | +57.2% |
| DHAR, MATASHA | 1 | 43.5% | +44.8% |
| JOHANSEN, PETER N. | 1 | 59.6% | +24.4% |
| ZHU, JIANJIAN | 1 | 58.1% | +82.5% |
| WEHBE, ANNE MARIE SABRINA | 1 | 57.3% | +43.3% |
| BURKHART, MICHAEL D | 1 | 62.4% | +11.8% |
| ANGELL, JON E | 1 | 71.1% | +21.0% |
| VIJAYARAGHAVAN, JAGAMYA NMN | 1 | 61.0% | +51.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17697028 | METHODS FOR IDENTIFYING GENOMIC SAFE HARBORS | VIJAYARAGHAVAN, JAGAMYA NMN | 91d overdue |
| 17047621 | SYSTEMS AND METHODS FOR DETECTING CANCER VIA cfDNA SCREENING | CHUNDURU, SURYAPRABHA | 17d overdue |
| 17776498 | CLASSIFIER MODELS TO PREDICT TISSUE OF ORIGIN FROM TARGETED TUMOR DNA SEQUENCING | ELKINS, BLAKE HARRISON | 2d overdue |
| 17914731 | SYSTEMS AND METHODS FOR DISTINGUISHING PATHOLOGICAL MUTATIONS FROM CLONAL HEMATOPOIETIC MUTATIONS IN PLASMA CELL-FREE DNA BY FRAGMENT SIZE ANALYSIS | BAILEY, STEVEN WILLIAM | 15d |
| 17681113 | METHODS OF GENERATING AND ISOLATING MIDBRAIN DOPAMINE NEURONS | TRAN, KHOA NHAT | — |
| 17526812 | MESOTHELIN CARS AND USES THEREOF | DIBRINO, MARIANNE | — |
| 17319495 | STEM CELL-BASED MULTIPLEX METHODS AND COMPOSITIONS | TRAN, KHOA NHAT | — |
| 17095216 | METHODS FOR IDENTIFYING ANTIGEN-SPECIFIC T CELL RECEPTORS | SINGH, ANOOP KUMAR | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17697044 | GENOMIC SAFE HARBORS FOR TRANSGENE INTEGRATION | ANGELL, JON E | 156d overdue |
| 17697028 | METHODS FOR IDENTIFYING GENOMIC SAFE HARBORS | VIJAYARAGHAVAN, JAGAMYA NMN | 91d overdue |
| 17514742 | NON-INVASIVE METHODS FOR SELECTIVELY ENRICHING PLURIPOTENT CELLS | TICHY, JENNIFER M.H. | 4d overdue |
| 18506518 | ANTIGEN-BINDING PROTEINS TARGETING MELANOMA DIFFERENTIATION ANTIGENS AND USES THEREOF | JOHANSEN, PETER N. | 28d |
| 18118072 | METHODS AND COMPOSITIONS FOR DETECTING RISK OF CANCER RELAPSE | BURKHART, MICHAEL D | 41d |
| 18947597 | USE OF PHOSPHOINOSITIDE 3-KINASE INHIBITORS FOR TREATMENT OF VASCULAR MALFORMATIONS | NEAGU, IRINA | — |
| 18799294 | METHODS OF IN VITRO DIFFERENTIATION OF MIDBRAIN DOPAMINE (MDA) NEURONS | DHAR, MATASHA | — |
| 18647236 | METHODS FOR MODULATING CELL PLURIPOTENCY AND SELF-RENEWAL PROPERTY | TICHY, JENNIFER M.H. | — |
| Art Unit | Apps |
|---|---|
| 1632 | 4 |
| 1644 | 4 |
| 1642 | 3 |
| 1653 | 2 |
| 1634 | 2 |
| 1638 | 2 |
| 1637 | 2 |
| 1633 | 2 |
| 1643 | 2 |
| 1675 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18947597 | USE OF PHOSPHOINOSITIDE 3-KINASE INHIBITORS FOR TREATMENT OF VASCULAR MALFORMATIONS | NEAGU, IRINA | 1629 | §103 | Non-Final OA | — | Pending | Nov 14, 2024 |
| 18799294 | METHODS OF IN VITRO DIFFERENTIATION OF MIDBRAIN DOPAMINE (MDA) NEURONS | DHAR, MATASHA | 1632 | §112DP | Non-Final OA | — | Pending | Aug 09, 2024 |
| 18647236 | METHODS FOR MODULATING CELL PLURIPOTENCY AND SELF-RENEWAL PROPERTY | TICHY, JENNIFER M.H. | 1653 | §103 | Non-Final OA | — | Pending | Apr 26, 2024 |
| 18506518 | ANTIGEN-BINDING PROTEINS TARGETING MELANOMA DIFFERENTIATION ANTIGENS AND USES THEREOF | JOHANSEN, PETER N. | 1644 | §103 | Final Rejection | 28d | Pending | Nov 10, 2023 |
| 18188795 | IL-33 SECRETING IMMUNORESPONSIVE CELLS AND USES THEREOF | ZHU, JIANJIAN | 1631 | §103DP | Non-Final OA | — | Pending | Mar 23, 2023 |
| 18182258 | METHOD TO REDUCE ONCOGENIC POTENTIAL OF INDUCED PLURIPOTENT STEM CELLS FROM AGED DONORS | WEHBE, ANNE MARIE SABRINA | 1634 | §112 | Non-Final OA | — | Pending | Mar 10, 2023 |
| 18118072 | METHODS AND COMPOSITIONS FOR DETECTING RISK OF CANCER RELAPSE | BURKHART, MICHAEL D | 1638 | §112 | Non-Final OA | 41d | Pending | Mar 06, 2023 |
| 17697044 | GENOMIC SAFE HARBORS FOR TRANSGENE INTEGRATION | ANGELL, JON E | 1637 | §112 | Final Rejection | 156d overdue | Pending | Mar 17, 2022 |
| 17697028 | METHODS FOR IDENTIFYING GENOMIC SAFE HARBORS | VIJAYARAGHAVAN, JAGAMYA NMN | 1633 | §101§103§112 | Non-Final OA | 91d overdue | Pending | Mar 17, 2022 |
| 17681113 | METHODS OF GENERATING AND ISOLATING MIDBRAIN DOPAMINE NEURONS | TRAN, KHOA NHAT | 1632 | §103§112 | Non-Final OA | — | Pending | Feb 25, 2022 |
| 17526812 | MESOTHELIN CARS AND USES THEREOF | DIBRINO, MARIANNE | 1641 | §103§112Other | Final Rejection | — | Pending | Nov 15, 2021 |
| 17514742 | NON-INVASIVE METHODS FOR SELECTIVELY ENRICHING PLURIPOTENT CELLS | TICHY, JENNIFER M.H. | 1653 | §103DP | Final Rejection | 4d overdue | Pending | Oct 29, 2021 |
| 17405613 | COMBINATIONS OF MULTIPLE CHIMERIC ANTIGEN RECEPTORS FOR IMMUNOTHERAPY | GEORGE, DENNIS CHERIAN | 1644 | §103§112DP | Final Rejection | — | Pending | Aug 18, 2021 |
| 17400689 | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY | WU, JULIE ZHEN QIN | 1643 | §103 | Final Rejection | 33d | Pending | Aug 12, 2021 |
| 17319495 | STEM CELL-BASED MULTIPLEX METHODS AND COMPOSITIONS | TRAN, KHOA NHAT | 1632 | §101§103§112 | Final Rejection | — | Pending | May 13, 2021 |
| 17213830 | STEM CELL-DERIVED HUMAN MICROGLIAL CELLS, METHODS OF MAKING AND METHODS OF USE | WANG, CHANG YU | 1675 | §103 | Non-Final OA | — | Pending | Mar 26, 2021 |
| 17095216 | METHODS FOR IDENTIFYING ANTIGEN-SPECIFIC T CELL RECEPTORS | SINGH, ANOOP KUMAR | 1632 | §103§112 | Non-Final OA | — | Pending | Nov 11, 2020 |
| 16576956 | STEM CELL-DERIVED ASTROCYTES, METHODS OF MAKING AND METHODS OF USE | WILSON, MICHAEL C | 1638 | §102§103§112 | Final Rejection | — | Pending | Sep 20, 2019 |
| 18750485 | RECOMBINANT MVA OR MVADELE3L EXPRESSING HUMAN FLT3L AND USE THEREOF AS IMMUNO-THERAPEUTIC AGENTS AGAINST SOLID TUMORS | ZOU, NIANXIANG | 1671 | §103§112Other | Non-Final OA | — | Pending | Jun 21, 2024 |
| 18707578 | IL33 PROTEINS AND METHODS OF USE THEREOF | ABBAS, SYED JARAR | 1674 | §102§112 | Non-Final OA | — | Pending | May 04, 2024 |
| 18392127 | METHODS AND COMPOSITIONS FOR TREATING CANCER | MOSELEY II, NELSON B | 1642 | §103DP | Non-Final OA | — | Pending | Dec 21, 2023 |
| 18523490 | IMMUNOGENIC WT-1 PEPTIDES AND METHODS OF USE THEREOF | ESSEX, LAURA ANN | 1647 | §103§112 | Non-Final OA | — | Pending | Nov 29, 2023 |
| 17792557 | METHODS AND COMPOSITIONS FOR CANCER IMMUNOTHERAPY | LEE, CHIHYI NMN | 1628 | §103§112 | Non-Final OA | — | Pending | Jun 20, 2023 |
| 18250607 | PATIENT-SPECIFIC THERAPEUTIC PREDICTIONS THROUGH ANALYSIS OF FREE TEXT AND STRUCTURED PATIENT RECORDS | WASEEM, HUMA | 3686 | §101§103 | Final Rejection | — | Pending | Apr 26, 2023 |
| 18138545 | COMBINATION THERAPY WITH MEK INHIBITOR AND CDK4/6 INHIBITOR TO TREAT PANCREATIC CANCER | HUTTER, GILLIAN A | 1625 | §112 | Final Rejection | 30d | Pending | Apr 24, 2023 |
| 18249914 | SYNTHETIC INTRONS FOR TARGETED GENE EXPRESSION | CANDELARIA, JULIANA IRENE | 1634 | §103§112 | Final Rejection | — | Pending | Apr 20, 2023 |
| 18249248 | INDUCTION OF FERROPTOSIS FOR CANCER THERAPY | HUDSON, AMY ROSE | 1636 | §102§103§112 | Non-Final OA | — | Pending | Apr 15, 2023 |
| 18043527 | METHODS AND COMPOSITIONS FOR TARGETING CYTOSOLIC DSDNA SIGNALING IN CHROMOSOMALLY UNSTABLE CANCERS | DUFFY, BRADLEY | 1643 | §102 | Non-Final OA | — | Pending | Feb 28, 2023 |
| 18003646 | C825 EXPRESSING IMMUNE CELLS AND DIAGNOSTIC USES THEREOF | POPA, ILEANA | 1633 | DP | Non-Final OA | 15d | Pending | Dec 28, 2022 |
| 17914731 | SYSTEMS AND METHODS FOR DISTINGUISHING PATHOLOGICAL MUTATIONS FROM CLONAL HEMATOPOIETIC MUTATIONS IN PLASMA CELL-FREE DNA BY FRAGMENT SIZE ANALYSIS | BAILEY, STEVEN WILLIAM | 1687 | §101§103§112 | Final Rejection | 15d | Pending | Sep 26, 2022 |
| 17911093 | DIGITAL PATHOLOGY RECORDS DATABASE MANAGEMENT | WORKU, SARON MATTHEWOS | 2408 | §103 | Final Rejection | — | Pending | Sep 12, 2022 |
| 17909310 | ANTI-CCR8 AGENTS | SULLIVAN, DENNIS JOHN | 1642 | §112 | Final Rejection | 14d | Pending | Sep 02, 2022 |
| 17794340 | INTRAOPERATIVE 2D/3D IMAGING PLATFORM | RAYMOND, KEITH MICHAEL | 3798 | §103§112 | Final Rejection | — | Pending | Jul 21, 2022 |
| 17814205 | IMMUNOGENIC WT-1 PEPTIDES AND METHODS OF USE THEREOF | SKELDING, ZACHARY S | 1644 | Other | Non-Final OA | 56d overdue | Pending | Jul 21, 2022 |
| 17745588 | DETERMINANTS OF CANCER RESPONSE TO IMMUNOTHERAPY | OUSPENSKI, ILIA I | 1644 | §102§112 | Non-Final OA | — | Pending | May 16, 2022 |
| 17776498 | CLASSIFIER MODELS TO PREDICT TISSUE OF ORIGIN FROM TARGETED TUMOR DNA SEQUENCING | ELKINS, BLAKE HARRISON | 1687 | §102§103 | Final Rejection | 2d overdue | Pending | May 12, 2022 |
| 17626941 | METHODS AND COMPOSITIONS FOR TARGETING TGF-ß SIGNALING IN CD4+ HELPER T CELLS FOR CANCER IMMUNOTHERAPY | LU, CHENG | 1642 | §103§112 | Non-Final OA | — | Pending | Jan 13, 2022 |
| 17549811 | METHODS AND COMPOSITIONS FOR REDUCING VANCOMYCIN-RESISTANT ENTEROCOCCI INFECTION OR COLONIZATION | MOAZZAMI, NAGHMEH NINA | 1652 | §103 | Final Rejection | — | Pending | Dec 13, 2021 |
| 17611805 | METHODS FOR PREDICTING RESPONSIVENESS OF CANCER TO FERROPTOSIS-INDUCING THERAPIES | BAUSCH, SARAE L | 1699 | §103§112 | Final Rejection | — | Pending | Nov 16, 2021 |
| 17428322 | COMPOSITIONS FOR SUPPRESSING TRIM28 AND USES THEREOF | PERSONS, JENNA L | 1637 | §112 | Final Rejection | 85d overdue | Pending | Aug 04, 2021 |
| 17196631 | METHODS AND COMPOSITIONS FOR DETECTION OF HPV DNA AND DIAGNOSIS AND MONITORING OF HPV-ASSOCIATED CANCERS | HANEY, AMANDA MARIE | 1682 | §103 | Non-Final OA | 7d | Pending | Mar 09, 2021 |
| 17259800 | METHODS OF USING PHARMACOLOGIC INHIBITORS OF TYPE 2 CYTOKINE SIGNALING TO TREAT OR PREVENT PANCREATIC CANCER | BERHANE, SELAM | 1675 | §103 | Non-Final OA | 89d overdue | Pending | Jan 12, 2021 |
| 17047621 | SYSTEMS AND METHODS FOR DETECTING CANCER VIA cfDNA SCREENING | CHUNDURU, SURYAPRABHA | 1681 | §101§103 | Final Rejection | 17d overdue | Pending | Oct 14, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMemorial Sloan Kettering Cancer Center has 43 pending office actions as of October 2026, spread across 27 art units and 41 examiners.
Jennifer M.H. Tichy has the most, with 2 of Memorial Sloan Kettering Cancer Center's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
